The potential for bioterrorism involving smallpox has led to a debate about the durability of protective immunity against smallpox from vaccination. By assessing the T cell reactivity to vaccinia virus in a healthy population, we show that subjects who were vaccinated within the past 3 decades and who have a visible vaccination scar had remarkable T cell reactivity. However, person who were vaccinated within the past 3 decades but who do not have a scar and those who were vaccinated 14 decades ago had responses as low as those in unvaccinated subjects. Thus, we estimate that the significant T cell memory response to vaccinia virus from successful vaccination may persist for only 20-30 years. Furthermore, we found the vaccinia-specific cellular immunity could be easily assessed by determination of the frequencies of vaccinia-specific CD69 expression on T cell subsets. These data may help in the development of public health strategies to counter bioterrorism threats associated with smallpox.
Smallpox was declared to have been eradicated in 1980, and routine vaccination with vaccinia virus was discontinued 120 years ago in most countries. The potential for a bioterrorist attack using smallpox has led to a debate about the durability of protective immunity against smallpox from vaccination [1] [2] [3] [4] [5] . The immunity acquired from vaccination is assumed by some experts to decline rapidly, but some recent studies have suggested that protection may persist for many decades [1, 3, 5] . The controversy has caused concern within the policy establishment about who should receive vaccines first if an outbreak occurs when supplies are limited [1] .
In Taiwan, nationwide routine and compulsory smallpox vaccination with Lister strain had been conducted for 15 decades and was stopped in 1979. Because the smallpox vaccines were no longer manufactured after 1981, the supply of smallpox vaccines would be severely limited in Taiwan if an outbreak were to occur and if mass vaccination were needed. In preparation for possible bioterrorist attacks using smallpox, we need to know how much protection remains in the current population. To approach this issue, we conducted a cross-sectional study to determine the immunological memory responses to vaccinia virus in our current population. Because T cells have been recognized to play a central role in the success of smallpox vaccination and in vaccinia infection [6] [7] [8] , we assessed vacciniaspecific CD4 + T cell responses using lymphocyte proliferation assays and CD8 + T cell responses by measuring vaccinia-specific cytotoxic T lymphocyte (CTL) activity. Furthermore, for possible large-scale population studies in the future, we attempted to develop a time-saving and relatively easy-to-use assay to quantitatively assess vaccinia-specific cellular immunity in this study.
SUBJECTS AND METHODS
Study subjects. From July 2002 through December 2002, we enrolled 220 healthy subjects from our general population without specific selection criteria other than age. We grouped the subjects into the following 5 age groups: 18-22 years (group A; 20 subjects), 23-30 years (group B; 50 subjects), 31-40 years (group C; 50 subjects), 41-50 years (group D; 50 subjects), and 51-70 years (group E; 50 subjects). Subjects in group A had been born after discontinuation of the smallpox vaccination program, so they never received smallpox vaccination. All subjects in the other age groups had received primary vaccination and had been revaccinated during childhood; they were subdivided in each age group on the basis of whether a vaccination scar was present, which may be a marker for the success of primary smallpox vaccination. Informed consent was obtained from all enrolled subjects, and the human experimentation guidelines of the US Department of Health and Human Services were followed in the conduct of clinical research. Measurement of vaccinia-specific CD4 + T cell reactivity. The vaccinia-specific CD4 + T cell response was assessed using lymphocyte proliferation assays by determining the frequencies of CD4 + T cells with bromodeoxyuridine (BrdU) incorporation after stimulation by vaccinia virus (BrdU Flow Kit; BD PharMingen), as described elsewhere [9, 10] . PBMCs were prepared from whole blood samples and were isolated by differential centrifugation over Ficoll-Paque (Pharmacia Biotech). PBMCs (10 6 per well in a 96-well round-bottom plate) were incubated for 6 days at 37ЊC with 5 mL of vaccinia virus (1.0 pfu/cell, prepared as 10 8 pfu in 500 mL of reconstituting fluid; Lister strain [kindly provided by the Center for Disease Control, Taipei, Republic of China]) or 5 mL of reconstituting fluid (0.01 mol/L of citric acid, 0.01 mol/L of sodium phosphate, and 40% glycerol), alone or with mitogen, in a final volume of 200 mL of complete RPMI 1640 medium. Phorbol myristate acetate (PMA; 5 ng/mL; Sigma) and calcium ionophore (500 ng/mL; Sigma) were used as mitogens. BrdU (final concentration, 10 mmol/L) was added 24 h before harvest. The cells with BrdU incorporation were detected by flow cytometry. PBMCs were stained with fluorescein-conjugated monoclonal antibodies to CD4 (CyChrome) and then fixed with paraformaldehyde, permeablized with saponin, and stained with anti-BrdU-FITC, in accordance with the BrdU Flow Kit staining protocol from the manufacturer. A total of 50,000 events were analyzed for each sample. The vaccinia-specific lymphoproliferative response of Measurement of vaccinia-specific CD8 + T cell reactivity. CD8 + T cells were separately isolated from PBMCs using immunomagnetic methods (CD8 Positive Isolation; Dynal A.S.) in accordance with the manufacturer's recommendations. After analysis by flow cytometry, the purity of CD8 + T cells was 199%. Isolated CD8 + T cells ( per well) were prepared as ef- 5 5 ϫ 10 fector cells by incubation with autologous monocytes (as antigen-presenting cells; ratio, 5:1) with vaccinia virus (1.0 pfu/ monocyte), in a final volume of 1 mL of complete RPMI 1640 medium in 24-well plates for 7 days. In our observation, a ratio of antigen-presenting cells (APCs) to T cells of 1:5 was needed to achieve enough stimulation of CD8 + T cells. If the ratio of APCs to T cells was less than 1:5 (i.e., 1:20, 1:50, or 1:100), the induced CTL activity may be variable or undetectable. Autologous monocytes were prepared as target cells (10 6 monocytes/mL) by being pulsed with vaccinia virus (1.0 pfu/cell) or with 5 mL of reconstituting fluid alone in 24-well plates (1 mL/ well) for 24 h of incubation. In this study, a nonradioactive lactate dehydrogenase (LDH)-release cytotoxicity assay kit (CytoTox 96 Non-Radioactive Cytotoxicity Assay; Promega) was used, with an effector/target ratio 10:1, in accordance with the manufacturer's instructions. An E/T ratio of 10:1 has the most interpretable data for the LDH-releasing cytotoxicity as- Frequencies of vaccinia-specific CD69 expression on T cell subsets. PBMCs (10 6 PBMCs/mL) were suspended in complete RPMI 1640 medium (Gibco) supplemented with penicillin-streptomycin and 10% fetal calf serum (Gibco) onto 24-well plates (1 mL/well). PBMCs were incubated with 5 mL of vaccinia virus (1.0 pfu/cell, prepared as 10 8 pfu in 500 mL of reconstituting fluid) or 5 mL of reconstituting fluid alone, in a final volume of 1 mL of complete RPMI 1640 medium. After 24 h of incubation at 37ЊC, PBMCs were stained with fluorescein-conjugated monoclonal antibodies to CD4 (CyChrome), CD8 (PE), and CD69 (FITC; PharMingen) and were then analyzed by flow cytometry (Becton Dickinson). CD69 may be the earliest activation marker for human lymphocytes [11] . However, unlike mitogen stimulation, 24 h of incubation is needed for an antigen stimulation to reach a steady and plateau expression of CD69 [12] . Incubation of an antigen for !24 h may lead to inconsistent results. PBMCs were gated into the lymphocyte population (by forward and side scatter) and were sequentially gated into CD4 + or CD8 + cells; they were then were analyzed to determine the frequencies of CD69 expression. A total of 50,000 events were analyzed for each sample. The frequencies of vaccinia-specific CD69 expression were calculated as follows: [the frequency of CD69 expression when incubated Statistical analysis. Statistical analysis was performed using SPSS statistical software, version 6.1.3 (SPSS). For analysis of continuous data, the nonparametric Mann-Whitney U test was used. Linear correlation was evaluated by Pearson's correlation coefficient. All tests were 2-tailed, and a significance level of .05 was used.
RESULTS

Age distribution of vaccinia-specific T cell responses.
The distribution of T cell reactivity against vaccinia virus in each age group reveals some important points ( figure 1, top and  bottom) . First, vaccinia-specific CD4 + and CD8 + T cell responses obviously decline with age; only the subjects in group B with a vaccination scar had remarkable T cell responses to vaccinia virus. Second, in both group B and group C, the T cell responses in subjects with a vaccination scar were significantly higher than were those in subjects without a scar (for CD4 + T cell responses in groups B and C, and Ϫ16 P p 1.48 ϫ 10 , respectively; for CD8 + T cell responses in groups Ϫ6
1.63 ϫ 10 B and C, and , respectively). How-
Ϫ16 Ϫ5
P p 1.08 ϫ 10 2.91 ϫ 10 ever, in group D and group E, the T cell responses in subjects with a vaccination scar are similar to those in subjects without a scar ( and .72, respectively). Third, subjects in group P p .57 A, who were never vaccinated with vaccinia virus and who were born after the eradication of smallpox, have low-level but detectable vaccinia-specific T cell responses similar to those in subjects without a scar in any other age group (P not shown). The data on T cell reactivity under mitogen stimulation showed that the results in all age groups were similar (data not shown) and that T cell reactivity did not wane with age.
Vaccinia-specific CD69 expression on T cell subsets. To know whether the vaccinia-specific T cell reactivity could be easily assessed by the frequencies of vaccinia-specific CD69 expression on T cell subsets, we compared the frequencies of vaccinia-specific CD69 expression on CD4 + T cells with the vaccinia-specific lymphoproliferative activity of CD4 + T cells, and the frequencies of vaccinia-specific CD69 expression on CD8 + T cells with the vaccinia-specific CD8 + CTL activity in 20 randomly selected subjects. We found that the frequencies of vaccinia-specific CD69 expression on CD4 + T cells could correlate well with the vaccinia-specific CD4 + lymphoproliferative responses ( figure 2, top) , and the relationship between the frequencies of vaccinia-specific CD69 expression on CD8 + T cells and the vaccinia-specific CD8 + CTL activity was also significant ( figure 2, bottom) .
DISCUSSION
Demkowicz and colleagues [4, 5] have shown that vacciniaspecific T cell immunity can persist for up to 50 years after immunization against smallpox in childhood in the presumed absence of exposure to vaccinia virus. However, we found that, although T cell reactivity may be detectable for many decades, T cell reactivity against vaccinia virus would start to wane within 20-30 years after smallpox vaccination. In some subjects, lack of a vaccination scar may indicate that they were never actually vaccinated or that their vaccinations were not successful. However, even though vaccinations are considered to have been successful on the basis of the presence of a vaccination scar, receipt of smallpox vaccination more than 3-4 decades ago may not provide current protection.
Currently available assays to evaluate vaccinia-specific reactivity of T cells, such as the proliferation assay, cytotoxicity assay, or immunospot assay [6] , are time-consuming, and some of them involve the handling of radioactive materials. In this study, we developed a time-saving and relatively easy-to-use assay to quantitatively assess vaccinia-specific cellular immunity. CD69, a member of the lectin superfamily of the transmembrane signal-transducing receptors, is the earliest activation surface marker on human lymphocytes [11] . Determination of the frequency of CD69 expression on T cell subsets after antigen stimulation by flow cytometry requires only 24 h of incubation and 2-3 h of handling, and it has been used for assessment of cellular immunity against tuberculosis and cytomegalovirus [9, 13] . Although CD69-expressing cells (after incubation with an antigen) may not necessarily be antigen-specific cells, here we show that the frequencies of CD69 expression on T cells after vaccinia virus stimulation do represent the extent of specific vaccinia-related activation. Thus, we propose that the frequencies of vaccinia-specific CD69 expression on T cell subsets may be a simple surrogate marker to measure vaccinia-specific T cell responses and that this may be useful tool to help evaluate protective immunity to smallpox in different populations.
The best way to determine the durability of immunological memory to vaccinia virus from smallpox vaccination is to conduct a longitudinal study with follow-up lasting for decades. However, it is impossible to rely on this kind of time-consuming study when there is the possibility that bioterrorism might happen at any time. Furthermore, it is difficult to determine how much T cell reactivity to vaccinia virus is enough to protect against smallpox or to reduce the disease severity. Because revaccination (boosting) does not induce a scar, and because revaccination was not clearly recorded in government documentation, it is difficult to assess the impact of revaccination on the durability of T cell reactivity. Despite the limitations listed above, these data imply that most people in the world may be more susceptible to smallpox than was previously expected [1, 3, 5] and that there is a lack of herd immunity, because most countries stopped providing smallpox vaccination 120 years ago. These data may help in the establishment of public health strategies and policy models to counter the threat of bioterrorism-associated smallpox.
